SEARCH

SEARCH BY CITATION

References

  • 1
    Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 18191827.
  • 2
    Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Hepatorenal syndrome: update on pathogenesis and treatment. A consensus workshop of the International Ascites Club. Gut 2007; 56: 13101318.
  • 3
    Arroyo V, Guevara M, Ginès P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 16581676.
  • 4
    Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000; 32(Suppl 1): 157170.
  • 5
    Schrier R, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988; 8: 11511157.
  • 6
    Bachmann-Brandt S, Bittner I, Neuhaus P, Frei U, Schindler R. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. Transpl Int 2000; 13: 357362.
  • 7
    Kapoor D, Redhead DN, Hayes PC, Webb DJ, Jalan R. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transpl 2003; 9: 3239.
  • 8
    Yanagisawa M, Kurihara H, Kimura Y, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411415.
  • 9
    Boss C, Bolli M, Weller T. Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications. Curr Med Chem 2002; 9: 349383.
  • 10
    Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 17741778.
  • 11
    Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. HEPATOLOGY 1992; 16: 9599.
  • 12
    Bernardi M, Gülberg V, Colantoni A, Trevisani F, Gasbarrini A, Gerbes AL. Plasma endothelin-1 and-3 in cirrhosis: relationship with systemic hemodynamics, renal function, and neurohumoral systems. J Hepatol 1996; 24: 161168.
  • 13
    Gerbes AL, Moller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis of the liver—role of splanchnic and renal passage and liver function. HEPATOLOGY 1995; 21: 735739.
  • 14
    Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 2002; 50: 111117.
  • 15
    Ozdogan O, Goren M, Ratip S, Giral A, Moini H, Enc F, et al. Role of endothelin-1 in a cirrhotic rat model with endotoxin induced acute renal failure. Hepatol Res 2002; 24: 114.
  • 16
    Soper CPR, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347: 18421843.
  • 17
    Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Löffler BM, et al. Pharmacology of tezosentan, new endothelin antagonist designed for parenteral use. J Pharmacol Exp Ther 1999; 290: 840846.
  • 18
    Clozel M, Clozel J-P, Hess P, Roux S, Sprecher U. Biochemical and hemodynamic effects of the endothelin antagonist tezosentan in dogs with aortic cross-clamping: Relationship to the dose. Allschwil, Switzerland: Actelion Pharmaceuticals Ltd Research; September 25, 2000. Research Report B-00.031.
  • 19
    Qiu C, Ding SS, Hess P, Clozel JP, Clozel M. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure. J Cardiovasc Pharmacol 2001; 38: 317324.
  • 20
    Karam H, Bruneval P, Clozel JP, Loffler BM, Bariety J, Clozel M. Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J Pharmacol Exp Ther 1995; 274: 481486.
  • 21
    Wilhelm SM, Stowe NT, Robinson AV, Schulak JA. The use of the endothelin receptor antagonist tezosentan before or after renal ischemia protects renal function. Transplantation 2001; 71: 211216.
  • 22
    Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, et al. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut 2004; 53: 18441849.
  • 23
    Moore KP, Wong F, Gines P, Ochs A, Bernardi M, Salerno F, et al. The management of ascites—report on the consensus conference of the International Ascites Club. HEPATOLOGY 2003; 38: 258266.
  • 24
    Minetti EE, Cozzi MG, Biella E, Napoli F, Guidi E. Evaluation of a short protocol for the determination of para-aminohippurate and inulin clearances. J Nephrol 1994; 7: 342346.
  • 25
    Cole BR, Giangiacomo J, Ingelfinger JR, Robson AM. Measurement of renal function without urine collection. A critical evaluation of the constant-infusion technic for determination of inulin and para-aminohippurate. N Engl J Med 1972; 287: 11091114.
  • 26
    Kuehnle HF, von Dahl K, Schmidt FH. Fully enzymatic inulin determination in small volume samples. Nephron 1992; 62: 104107.
  • 27
    Marsilio R, Dall'Amico R, Montini G, Murer L, Ros M, Zacchello G, et al. Rapid determination of p-aminohippuric acid in serum and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 704: 359364.
  • 28
    Fredline VF, Kovacs EM, Taylor PJ, Johnson AG. Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999; 45: 659664.
  • 29
    van Giersbergen PL, Wipfli P, Dingemanse J. Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 792: 369373.
  • 30
    Cardenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis 2006; 10: 371385.
  • 31
    Zaid A, Abassi ZA, Ellahham S, Winaver J, Hoffman A. The intrarenal endothelin system and hypertension. News Physiol Sci 2001; 16: 152156.
  • 32
    Firth JD, Ratcliffe PJ, Raine AE, Ledingham JG. Endothelin: an important factor in acute renal failure? Lancet 1988; 2: 11791182.
  • 33
    Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977; 37: 635642.
  • 34
    Vuurmans JL, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans. Nephrol Dial Transplant 2004; 19: 27422746.
  • 35
    Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003; 42: 140147.
  • 36
    Löffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993; 333: 108110.
  • 37
    Teerlink JR, Massie BM, Cleland JGF, et al. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure [Abstract]. Circulation 2001; 104: II526.
  • 38
    Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001; 3: 747750.
  • 39
    O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003; 41: 14521457.
  • 40
    Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double blind, placebo-controlled study. J Am Coll Cardiol 2003; 41: 204210.
  • 41
    Dingemanse J, Clozel M, van Giersbergen PL. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol 2002; 53: 355362.
  • 42
    Levin ER. Endothelins. N Engl J Med 1995; 333: 356363.
  • 43
    Cotter G, Kaluski E, Stangl K, Pacher R, Richter C, Milo-Cotter O, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004; 6: 601609.
  • 44
    Konrad D, Oldner A, Rossi P, Wanecek M, Rudehill A, Weitzberg E. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock. Crit Care Med 2004; 32: 11921199.
  • 45
    Helmy A, Newby DE, Jalan R, Hayes PC, Webb DJ. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003; 52: 410415.
  • 46
    Vaughan RB, Angus PW, Chin-Dusting JPF. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003; 52: 15051510.
  • 47
    Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006; 36(Suppl 3): 7888.